Mumbai, Oct. 30 -- Dr. Reddy's Laboratories (down 4.67%) and Shaily Engineering Plastics (down 11.29%) tumbled.

In a regulatory filing on Wednesday, Dr. Reddy's Laboratories said it has received a Notice of Non-Compliance (NON) from Canada's Pharmaceutical Drugs Directorate regarding its Semaglutide injection application, seeking additional information and clarifications. The company said it will respond promptly within the stipulated timeline and remains confident in the product's quality, safety, and comparability.

Semaglutide, a popular diabetes and weight-loss drug, is the generic version of Ozempic, developed by Novo Nordisk.

The update weighed on shares of Shaily Engineering Plastics, which manufactures drug delivery devices, inc...